UPDATE: Promising new combination therapies for HIV discussed at 14th CROI

The 14th Conference on Retroviruses and Opportunistic Infections, co-sponsored by the US Foundation for Retrovirology and Human Health and the Centers for Disease Control and Prevention (CDC), was dominated by clinical research presentations from some of the world's largest drug and biotechnology firms.

Pfizer's maraviroc impresses

In a keynote address, USA-based drug giant Pfizer reported data from a trial of its antiviral drug maraviroc indicating that nearly double the number of HIV-infected patients receiving it in combination with optimized background treatment achieved undetectable levels of virus, compared with those treated with OBT alone.